Skip to main content

Table 4 Assay results for the determination of SF and VP in pharmaceutical dosage forma using all the proposed methods (n = 5)

From: Eco-friendly analytical methods for the determination of compounds with disparate spectral overlapping: application to antiviral formulation of sofosbuvir and velpatasvir

  SF VP
2DD ΔA ΔD1 DC Reference method (Rezk et al., 2019b) NBD-Cl-UV NBD-Cl-Flu MBTH-UV Reference method (Attia et al., 2018)
λ (nm) 254 232 245 D1 273/D1 299 D1 273/D1 355 260 436 λem/ex, 550/480 709 339
% Recovery 101.0 100.5 100.4 100.2 99.8 99.1 99.8 100.4 99.8 100.9
SD 1.165 0.82 1.463 0.84 1.16 0.95 0.92 0.66 1.44 0.78
t test(b) 1.13 2.08 2.17 2.14 1.83 N/A 1.86 0.36 1.83 N/A
F test(b) 2.15 1.07 2.36 1.11 2.81 N/A 5.87 1.08 1.02 N/A
  1. (a)Epclusa® tablets reported to contain 400 mg SF and 100 mg VP
  2. (b)Theoretical values of t and F for p = 0.05 are 2.31 and 6.39, respectively
\